Clinicogenomic Landscape of Metastatic Thymic Epithelial Tumors
JCO Precision Oncology · 2023-02 · (7)
DOI: 10.1200/po.22.00465 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2023-02. Verfasst von Fatemeh Ardeshir-Larijani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN. Hauptthemen laut MEDLINE: Thymoma, Thymus Neoplasms, Carcinoma, Neoplasms, Glandular and Epithelial. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
BACKGROUND Despite favorable clinical outcomes, a subset of patients with thymic epithelial tumors (TETs) develop metastasis. The Cancer Genome Atlas (TCGA) provides genomic data on primary TETs (pTETs). This study assessed the molecular alterations and uncovered targetable pathways in metastatic TETs (mTETs). METHODS From 2015 to 2020, 49 patients with stage IV TETs underwent Clinical Laboratory Improvement Amendments–based sequencing using whole-exome sequencing (n = 33), panel-based testing (n = 12), and/or liquid biopsy (n = 24). Specimens were obtained from a metastatic organ (n = 36) or relapsed primary mediastinal mass (n = 10), whereas four patients underwent a liquid biopsy only. Data on pTETs were derived from the TCGA. RESULTS Compared with the pTET data set, patients with mTETs were younger (54 years v 60.5 years, P = .009) and had more aggressive histologies, with the most common tumor type being thymic carcinoma (n = 22, 40.7%) and B3 thymoma (n = 15, 27.8%). GTF2I was the most altered gene in primary thymomas (48.80%, n = 60). In metastatic thymoma and thymic carcinoma, TP53 was the most common genetic alteration (31% and 36%, respectively). In mTETs, the genomic alteration occurred in the TP53/CDK, EGFR/RAS, and PI3K/mTOR pathways. Biopsies obtained from distant metastasis were more commonly found to contain targetable mutations. There was an overlap of 61% (22 of 36) between tissue and liquid biopsy genomic alterations. CONCLUSION Clinically actionable genomic alterations are frequently observed in mTETs, indicating a value of repeat biopsy (preferably from a metastatic site of TETs for sequencing at the time of recurrence (TCGA data).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematology and Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN.
- Caris Life Sciences, Phoenix, AZ.
ORCID-Profile: Fatemeh Ardeshir-Larijani, Milan Radovich, Ashiq Masood, Huda Salman, Patrick J Loehrer
Förderung
- NCI NIH HHS
Zitieren
APA
Ardeshir-Larijani, F., Schneider, B. P., Althouse, S. K., Radovich, M., Masood, A., Perna, F., Salman, H., & Loehrer, P. J. (2023). Clinicogenomic Landscape of Metastatic Thymic Epithelial Tumors. JCO Precision Oncology. https://doi.org/10.1200/po.22.00465
Vancouver
Ardeshir-Larijani F, Schneider BP, Althouse SK, Radovich M, Masood A, Perna F, et al. Clinicogenomic Landscape of Metastatic Thymic Epithelial Tumors. JCO Precision Oncology. 2023. doi:10.1200/po.22.00465
BibTeX
@article{ArdeshirLarijani2023,
author = {Ardeshir-Larijani, Fatemeh and Schneider, Bryan P and Althouse, Sandra K and Radovich, Milan and Masood, Ashiq and Perna, Fabiana and Salman, Huda and Loehrer, Patrick J},
title = {Clinicogenomic Landscape of Metastatic Thymic Epithelial Tumors},
journal = {JCO Precision Oncology},
year = {2023},
number = {7},
doi = {10.1200/po.22.00465}
}
EUVIMED